Previous clinical trials, with a murine IgG2a anti-ICAM-1 antibody, targeting another ICAM-1 epitope than BI-505, enlimomab, have been performed, with the aim of reducing detrimental inflammatory activity in ischemic stroke, rheumatoid arthritis and burn injuries [33–36]. Here, ICAM1 is linked to ischemic stroke.